Harnessing preclinical models for the interrogation of ovarian cancer.
Harnessing preclinical models for the interrogation of ovarian cancer.
复制标题
利用临床前模型来研究卵巢癌
DOI:
10.1186/s13046-022-02486-z
复制
发表时间:
2022-09-16
影响因子:
11.3
通讯作者:
Sun, Chaoyang
中科院分区:
文献类型:
--
作者:
Qin, Tianyu;Fan, Junpeng;Lu, Funian;Zhang, Li;Liu, Chen;Xiong, Qiyue;Zhao, Yang;Chen, Gang;Sun, Chaoyang
关键词:
Ovarian cancer (OC) is a heterogeneous malignancy with various etiology, histopathology, and biological feature. Despite accumulating understanding of OC in the post-genomic era, the preclinical knowledge still undergoes limited translation from bench to beside, and the prognosis of ovarian cancer has remained dismal over the past 30 years. Henceforth, reliable preclinical model systems are warranted to bridge the gap between laboratory experiments and clinical practice. In this review, we discuss the status quo of ovarian cancer preclinical models which includes conventional cell line models, patient-derived xenografts (PDXs), patient-derived organoids (PDOs), patient-derived explants (PDEs), and genetically engineered mouse models (GEMMs). Each model has its own strengths and drawbacks. We focus on the potentials and challenges of using these valuable tools, either alone or in combination, to interrogate critical issues with OC.
登录
查看更多内容
影响因子:
4.7
作者:
Chen H;Gotimer K;De Souza C;Tepper CG;Karnezis AN;Leiserowitz GS;Chien J;Smith LH
通讯作者:
Smith LH
影响因子:
14.9
作者:
Conte, Nathalie;Mason, Jeremy C.;Bult, Carol C.
通讯作者:
Bult, Carol C.
影响因子:
3.7
作者:
Beaufort CM;Helmijr JC;Piskorz AM;Hoogstraat M;Ruigrok-Ritstier K;Besselink N;Murtaza M;van IJcken WF;Heine AA;Smid M;Koudijs MJ;Brenton JD;Berns EM;Helleman J
通讯作者:
Helleman J
影响因子:
11
作者:
Chang, Yu-Hsun;Chu, Tang-Yuan;Ding, Dah-Ching
通讯作者:
Ding, Dah-Ching
影响因子:
30.8
作者:
Ben-David U;Ha G;Tseng YY;Greenwald NF;Oh C;Shih J;McFarland JM;Wong B;Boehm JS;Beroukhim R;Golub TR
通讯作者:
Golub TR